engleski

Alloimunization following allogeneic hematopoietic stem cell transplantation

In almost all patients treated with allogeneic hematopoietic stem cell transplantation (HSCT), there is a certain degree of disparity in red blood cell (RBC) antigens. Major, minor and bidirectional ABO incompatibility can cause acute hemolysis or delayed erythropoiesis recovery in the post-transplant period. Non- ABO red blood cell alloantibodies may cause similar complications if the recipient or donor RBC expresses a specific antigen. New immunization after allogeneic HSCT, although rare in occurrence (1 to 8.7%), can also cause hemolysis. Aims: The aim was to investigate the frequency of non-ABO alloimmunization following allogeneic HSCT, the cause of their occurrence and the specificity of alloantibodies.

Allogeneic hematopoietic stem cell transplantation ; alloimmunization

nije evidentirano